Project Summary

Ilya Reznik, M.D. (Young Investigator 2002) of Sackler School of Medicine, will investigate the frequency of the enzyme serum creatine kinase (SCK) elevation in patients treated with atypical neuroleptics (olanzapine and risperidone) and a group receiving typical neuroleptic drugs (haloperidol and perphenazine) and evaluate them neurologically and electrophysiologically for possible muscular and peripheral nervous systems involvement, as marked elevations of SCK have been associated with treatment with both typical (classical) and novel (atypical) neuroleptic agents and it has been suggested that atypical antipsychotic drugs may cause skeletal muscle injury.  Dr. Reznik will attempt to clarify the particular role of these agents in producing significant muscular and neurological toxic influence in comparison with classical neuroleptics in patients with psychotic disorders. 

Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Psychotic Disorder

Search Again